Clinical trials
Scleroderma, Diffuse trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
79 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 14 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 9 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Unknown status | 13 |
| Recruiting | 10 |
| Terminated | 6 |
| Not yet recruiting | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lady Davis Institute | 9 |
| University of Michigan | 9 |
| Istanbul University | 6 |
| University Hospital, Strasbourg, France | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Assiut University | 2 |
| Firat University | 2 |
| Johns Hopkins University | 2 |
| Pamukkale University | 2 |
| Asociación Española de Esclerodermia | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Diffuse | 79 |
| Scleroderma, Systemic | 43 |
| Raynaud Disease | 4 |
| Fatigue | 3 |
| Scleroderma, Localized | 3 |
| Ulcer | 3 |
| Anxiety Disorders | 2 |
| Arthritis | 2 |
| Autoimmune Diseases | 2 |
| Cicatrix | 2 |
Trials
Showing 26 to 50 of 79. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.